Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Cerilliant
Johnson and Johnson
Covington
Teva
Boehringer Ingelheim
Julphar
Federal Trade Commission
QuintilesIMS
Farmers Insurance

Generated: December 12, 2017

DrugPatentWatch Database Preview

Forest Labs Company Profile

« Back to Dashboard

What is the competitive landscape for FOREST LABS, and what generic alternatives to FOREST LABS drugs are available?

FOREST LABS has forty-one approved drugs.

There are forty-eight US patents protecting FOREST LABS drugs and there have been eight Paragraph IV challenges on FOREST LABS drugs in the past three years.

There are four hundred and seventy patent family members on FOREST LABS drugs in fifty-three countries and twenty-two supplementary protection certificates in eleven countries.

Summary for Forest Labs

International Patents:470
US Patents:48
Tradenames:40
Ingredients:27
NDAs:41
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Forest Labs LlcNAMENDA XRmemantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL022525-004Jun 21, 2010ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Forest Labs IncZENPEPpancrelipase (amylase;lipase;protease)CAPSULE, DELAYED RELEASE;ORAL022210-005Jun 15, 2011RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Forest Labs IncFETZIMAlevomilnacipran hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL204168-003Jul 25, 2013RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Forest Labs LlcCANASAmesalamineSUPPOSITORY;RECTAL021252-002Nov 5, 2004ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Forest Labs LlcLINZESSlinaclotideCAPSULE;ORAL202811-001Aug 30, 2012RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Forest Labs LlcNAMZARICdonepezil hydrochloride; memantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL206439-003Jul 18, 2016RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Forest Labs LlcSAPHRISasenapine maleateTABLET;SUBLINGUAL022117-001Aug 13, 2009RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Forest Labs LlcNAMENDA XRmemantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL022525-003Jun 21, 2010ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Forest LabsSUS-PHRINE SULFITE FREEepinephrineINJECTABLE;INJECTION007942-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Forest Labs IncBENTYLdicyclomine hydrochlorideTABLET;ORAL007409-001Oct 15, 1984ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Forest Labs

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Forest Labs LlcNAMENDA XRmemantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL022525-001Jun 21, 2010► Subscribe► Subscribe
Forest Labs LlcPYLERAbismuth subcitrate potassium; metronidazole; tetracyclineCAPSULE;ORAL050786-001Sep 28, 2006► Subscribe► Subscribe
Forest LabsLEXAPROescitalopram oxalateTABLET;ORAL021323-001Aug 14, 2002► Subscribe► Subscribe
Forest Labs IncURSO 250ursodiolTABLET;ORAL020675-001Dec 10, 1997► Subscribe► Subscribe
Forest Labs LlcNAMENDA XRmemantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL022525-003Jun 21, 2010► Subscribe► Subscribe
Forest LabsLEXAPROescitalopram oxalateSOLUTION;ORAL021365-001Nov 27, 2002► Subscribe► Subscribe
Forest Labs LlcNAMENDAmemantine hydrochlorideTABLET;ORAL021487-001Oct 16, 2003► Subscribe► Subscribe
Forest Labs LlcNAMZARICdonepezil hydrochloride; memantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL206439-001Dec 23, 2014► Subscribe► Subscribe
Forest Labs LlcNAMENDA XRmemantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL022525-002Jun 21, 2010► Subscribe► Subscribe
Forest Labs LlcNAMENDA XRmemantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL022525-004Jun 21, 2010► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for FOREST LABS drugs

Drugname Dosage Strength Tradename Submissiondate
asenapine maleateSublingual Tablets2.5 mgSAPHRIS7/27/2017
levomilnacipranExtended-release Capsules20 mg, 40 mg, 80 mg and 120 mgFETZIMA7/25/2017
nebivolol hydrochloride and valsartanTablets5 mg/80 mgBYVALSON6/9/2017
memantine hydrochloride extended-release and donepezil hydrochlorideCapsules7 mg/10 mgNAMZARIC9/26/2016
memantine hydrochloride extended-release and donepezil hydrochlorideCapsules21 mg/10 mgNAMZARIC9/23/2016
linaclotideCapsules145 mcg and 290 mcgLINZESS8/30/2016
memantine hydrochloride extended-release and donepezil hydrochlorideCapsules14 mg/10 mg and 28 mg/10 mgNAMZARIC5/18/2015
vilazodone hydrochlorideTablets10 mg, 20 mg, and 40 mgVIIBRYD1/21/2015
bismuth subcitrate potassium, metronidazole, and tetracycline hydrochlorideCapsules140 mg/125 mg/ 125 mgPYLERA8/12/2014
memantine hydrochlorideExtended-release Capsules7 mg, 14 mg, 21 mg, and 28 mgNAMENDA XR8/16/2013
asenapine maleateSublingual Tablets5 mg and 10 mgSAPHRIS8/13/2013
memantine hydrochlorideExtended-release Capsules7 mg, 14 mg, 21 mgNAMENDA XR6/17/2013
memantine hydrochlorideExtended-release Capsules28 mgNAMENDA XR6/12/2013
memantine hydrochlorideExtended-release Capsules7 mg, 14 mg, 21 mg, and 28 mgNAMENDA XR6/10/2013
mesalamineSuppository1000 mgCANASA5/24/2013
nebivolol hydrochlorideTablets2.5 mg, 5 mg, 10 mg, and 20 mgBYSTOLIC12/19/2011
memantine hydrochlorideTablets5 mg and 10 mgNAMENDA10/16/2007
escitalopram oxalateCapsules5 mgLEXAPRO8/17/2005
escitalopram oxalateCapsules10 mg and 20 mgLEXAPRO3/30/2005

Non-Orange Book Patents for Forest Labs

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,426,472Method and composition for administering an NMDA receptor antagonist to a subject► Subscribe
2,012,058,182► Subscribe
9,624,204Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride► Subscribe
8,318,744Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride► Subscribe
7,772,188Methods and compositions for the treatment of gastrointestinal disorders► Subscribe
2,014,073,571► Subscribe
7,619,007Method and composition for administering an NMDA receptor antagonist to a subject► Subscribe
7,541,384Mesalamine suppository► Subscribe
8,921,375Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride► Subscribe
9,259,403Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Forest Labs Drugs

Country Document Number Estimated Expiration
Poland402987► Subscribe
Australia2002320822► Subscribe
Russian Federation2004100824► Subscribe
TunisiaSN05195► Subscribe
European Patent Office1397357► Subscribe
Poland219671► Subscribe
Taiwan200843795► Subscribe
Japan2010519217► Subscribe
South Korea101310037► Subscribe
World Intellectual Property Organization (WIPO)2006130174► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Forest Labs Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0593Netherlands► SubscribePRODUCT NAME: LINACLOTIDE; REGISTRATION NO/DATE: EU/1/12/801/001-004 20121126
02C/035Belgium► SubscribePRODUCT NAME: MEMANTINE; REGISTRATION NO/DATE: EU/1/02/219/001 20020517
2013013Lithuania► SubscribePRODUCT NAME: LINACLOTIDUM; REGISTRATION NO/DATE: EU/1/12/801/001 - EU/1/12/801/004 20121126
C/GB96/048United Kingdom► SubscribePRODUCT NAME: NEBIVOLOL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR HYDRATE; REGISTERED: NL RVG/19317 19951018; UK 00242/0309 19960509
2013 00027Denmark► Subscribe
2013000045Germany► SubscribePRODUCT NAME: LINACLOTID UND JEDE THERAPEUTISCH AEQUIVALENTE FORM DAVON, WELCHE DURCH DAS GRUNDPATENT GESCHUETZT IST, EINSCHLIESSLICH DESSEN PHARMAZEUTISCH VERTRAEGLICHE SALZE; REGISTRATION NO/DATE: EU/1/12/801/001-004 20121126
00594Netherlands► SubscribePRODUCT NAME: LINACLOTIDE; REGISTRATION NO/DATE: EU/1/12/801/001-004 20121126
C0038France► SubscribePRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
C/GB02/046United Kingdom► SubscribePRODUCT NAME: MEMANTINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS; REGISTERED: UK EU/1/02/219/001 20020515; UK EU/1/02/219/002 20020515; UK EU/1/02/219/003 20020515; UK EU/1/02/219/004 20020515; UK EU/1/02/219/005 20020515; UK EU/1/02/219/006 20020515
0594Netherlands► SubscribePRODUCT NAME: LINACLOTIDE; REGISTRATION NO/DATE: EU/1/12/801/001-004 20121126
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
US Army
Chinese Patent Office
Boehringer Ingelheim
Harvard Business School
Citi
Chubb
US Department of Justice
Farmers Insurance
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot